Navigation Links
New 'FeTRAM' is promising computer memory technology
Date:9/27/2011

WEST LAFAYETTE, Ind. - Researchers are developing a new type of computer memory that could be faster than the existing commercial memory and use far less power than flash memory devices.

The technology combines silicon nanowires with a "ferroelectric" polymer, a material that switches polarity when electric fields are applied, making possible a new type of ferroelectric transistor.

"It's in a very nascent stage," said doctoral student Saptarshi Das, who is working with Joerg Appenzeller, a professor of electrical and computer engineering and scientific director of nanoelectronics at Purdue's Birck Nanotechnology Center.

The ferroelectric transistor's changing polarity is read as 0 or 1, an operation needed for digital circuits to store information in binary code consisting of sequences of ones and zeroes. The new technology is called FeTRAM, for ferroelectric transistor random access memory.

"We've developed the theory and done the experiment and also showed how it works in a circuit," he said. Findings are detailed in a research paper that appeared this month in Nano Letters, published by the American Chemical Society.

The FeTRAM technology has nonvolatile storage, meaning it stays in memory after the computer is turned off. The devices have the potential to use 99 percent less energy than flash memory, a non-volatile computer storage chip and the predominant form of memory in the commercial market.

"However, our present device consumes more power because it is still not properly scaled," Das said. "For future generations of FeTRAM technologies one of the main objectives will be to reduce the power dissipation. They might also be much faster than another form of computer memory called SRAM."

The FeTRAM technology fulfills the three basic functions of computer memory: to write information, read the information and hold it for a long period of time.

"You want to hold memory as long
'/>"/>

Contact: Emil Venere
venere@purdjue.edu
765-494-4709
Purdue University
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
3. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
4. Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
5. New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando
6. INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
7. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
8. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. NeoStem Featured in Business Week; Promising Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article
11. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New 'FeTRAM' is promising computer memory technology
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Calif., Feb. 24, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... American Journal of Clinical Pathology demonstrated the ... HPV-16 and HPV-18, two of the highest risk HPV genotypes causing ... for Advanced HPV Diagnostics) study, which involved more than 47,000 women, ...
... Reportlinker.com announces that a new market research report ... Propylene Oxide: 2010 World Market Outlook And Forecast ... The report analyzes worldwide markets for Propylene oxide, ... It provides the most complete and current analytical ...
... (OTC Bulletin Board: OMBP):  Omni Bio Pharmaceutical, Inc. ("Omni ... James Crapo will become its Chief Executive Officer.  The ... Crapo as a director in the near term.  Dr. ... Chief Executive Officer since its inception in March 2009, ...
Cached Biology Technology:Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer 2Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer 3Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Omni Bio Pharmaceutical Realigns Management 2Omni Bio Pharmaceutical Realigns Management 3Omni Bio Pharmaceutical Realigns Management 4
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Assistance Foundation (AHAF, www.ahaf.org ), a nonprofit organization ... vision diseases, announced today that it has awarded 21 ... are studying glaucoma and macular degeneration. The two ... the world. "AHAF is known for pinpointing ...
... connection between the sickle cell trait and sudden cardiac ... observed in black military recruits 25 years ago, a ... confirms this risk for these individuals during competitive sports. ... African Americans are tested at birth, affects approximately 8 ...
... plants that suck water, nutrients and information from other plants ... of California, Davis, have now shown that they can make ... parasite taps into the host. "We think that this ... of plant biology at UC Davis, who led the project. ...
Cached Biology News:American Health Assistance Foundation announces grants to advance promising vision research 2American Health Assistance Foundation announces grants to advance promising vision research 3American Health Assistance Foundation announces grants to advance promising vision research 4Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 3Hitting back at 'wiretapping' parasite 2
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
... DCTD_HUMAN GI Number: 4503277 ... 20016 Description: FUNCTION: Supplies the ... ACTIVITY: dCMP + H 2 O ... SUBUNIT: Homohexamer. SIMILARITY: Belongs to the ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
adult...
Biology Products: